{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.ai-analytics.org/api/v1/entity/DYN/timeline","_source":{"data_provider":"AI Analytics","data_provider_url":"https://api.ai-analytics.org","license":"https://api.ai-analytics.org/license","usage_info":"https://api.ai-analytics.org/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-09-22T11:59:04.143Z","methodology_url":"https://api.ai-analytics.org/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":7074,"canonical_name":"Dyne Therapeutics, Inc.","cik":"0001818794","uei":null,"lei":null,"duns":null,"ticker":"DYN"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","open.payments","dol.form5500","hud.housing","irs.bmf"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":105,"clinical":1},"count":100,"timeline":[{"ts":"2026-07-22","kind":"sec.filing","form_type":"8-K","title":"8-K — Dyne Therapeutics, Inc. — 2026-07-22","url_slug":"/sec/cik-0001818794/8-k/0001193125-26-312571","accession_number":"0001193125-26-312571","importance":35},{"ts":"2026-07-22","kind":"sec.filing","form_type":"424B5","title":"424B5 — Dyne Therapeutics, Inc. — 2026-07-22","url_slug":"/sec/cik-0001818794/424b5/0001193125-26-312576","accession_number":"0001193125-26-312576","importance":30},{"ts":"2026-07-21","kind":"sec.filing","form_type":"424B5","title":"424B5 — Dyne Therapeutics, Inc. — 2026-07-21","url_slug":"/sec/cik-0001818794/424b5/0001193125-26-310573","accession_number":"0001193125-26-310573","importance":30},{"ts":"2026-07-20","kind":"sec.filing","form_type":"8-K","title":"8-K — Dyne Therapeutics, Inc. — 2026-07-20","url_slug":"/sec/cik-0001818794/8-k/0001193125-26-308343","accession_number":"0001193125-26-308343","importance":35},{"ts":"2026-07-07","kind":"sec.form144","reporter":"Atlas Venture Fund XI, LP","title":"Shareholder","shares":153966,"usd_value":3516583,"security_title":"Common","approx_sale_date":"2026-07-07","accession_number":"0001628280-26-047533","importance":40.703316688},{"ts":"2026-07-07","kind":"sec.form144","reporter":"Atlas Venture Opportunity Fund II, LP","title":"Shareholder","shares":77387,"usd_value":1767519,"security_title":"Common","approx_sale_date":"2026-07-07","accession_number":"0001628280-26-047532","importance":40.353503816},{"ts":"2026-07-07","kind":"sec.form144","reporter":"Atlas Venture Opportunity Fund I, LP","title":"Shareholder","shares":60858,"usd_value":1389997,"security_title":"Common","approx_sale_date":"2026-07-07","accession_number":"0001628280-26-047534","importance":40.277999344},{"ts":"2026-07-07","kind":"sec.form144","reporter":"ATLAS VENTURE ASSOCIATES XI, L.P.","title":"Shareholder","shares":5000,"usd_value":114200,"security_title":"Common","approx_sale_date":"2026-07-07","accession_number":"0001628280-26-047536","importance":40.02284},{"ts":"2026-07-07","kind":"sec.insider.s","reporter":"Rhodes Jason P","title":"","shares":124379,"price_per_share":23.17,"usd_value":2881861,"security_title":"Common Stock","importance":37.88186143},{"ts":"2026-07-07","kind":"sec.insider.s","reporter":"Rhodes Jason P","title":"","shares":62543,"price_per_share":23.17,"usd_value":1449121,"security_title":"Common Stock","importance":36.44912131},{"ts":"2026-07-07","kind":"sec.insider.s","reporter":"Rhodes Jason P","title":"","shares":49193,"price_per_share":23.17,"usd_value":1139802,"security_title":"Common Stock","importance":36.13980181},{"ts":"2026-07-07","kind":"sec.insider.s","reporter":"Rhodes Jason P","title":"","shares":29587,"price_per_share":23.62,"usd_value":698845,"security_title":"Common Stock","importance":35.69884494},{"ts":"2026-07-07","kind":"sec.insider.s","reporter":"Rhodes Jason P","title":"","shares":14844,"price_per_share":23.62,"usd_value":350615,"security_title":"Common Stock","importance":35.35061528},{"ts":"2026-07-07","kind":"sec.insider.s","reporter":"Rhodes Jason P","title":"","shares":11665,"price_per_share":23.62,"usd_value":275527,"security_title":"Common Stock","importance":35.2755273},{"ts":"2026-07-07","kind":"sec.insider.s","reporter":"Rhodes Jason P","title":"","shares":5000,"price_per_share":23.61,"usd_value":118050,"security_title":"Common Stock","importance":35.11805},{"ts":"2026-07-07","kind":"sec.filing","form_type":"144","title":"144 — Dyne Therapeutics, Inc. — 2026-07-07","url_slug":"/sec/cik-0001818794/144/0001628280-26-047532","accession_number":"0001628280-26-047532","importance":30},{"ts":"2026-07-06","kind":"sec.form144","reporter":"Atlas Venture Fund XI, LP","title":"Shareholder","shares":253039,"usd_value":5837610,"security_title":"Common","approx_sale_date":"2026-07-06","accession_number":"0001628280-26-047357","importance":41.167521946},{"ts":"2026-07-06","kind":"sec.insider.s","reporter":"Rhodes Jason P","title":"","shares":253039,"price_per_share":22.79,"usd_value":5766759,"security_title":"Common Stock","importance":40.76675881},{"ts":"2026-07-06","kind":"sec.form144","reporter":"Atlas Venture Opportunity Fund II, LP","title":"Shareholder","shares":127182,"usd_value":2934089,"security_title":"Common","approx_sale_date":"2026-07-06","accession_number":"0001628280-26-047355","importance":40.586817748},{"ts":"2026-07-06","kind":"sec.form144","reporter":"Atlas Venture Opportunity Fund I, LP","title":"Shareholder","shares":100019,"usd_value":2307438,"security_title":"Common","approx_sale_date":"2026-07-06","accession_number":"0001628280-26-047358","importance":40.461487666},{"ts":"2026-07-06","kind":"sec.insider.s","reporter":"Rhodes Jason P","title":"","shares":127182,"price_per_share":22.79,"usd_value":2898478,"security_title":"Common Stock","importance":37.89847778},{"ts":"2026-07-06","kind":"sec.insider.s","reporter":"Rhodes Jason P","title":"","shares":100019,"price_per_share":22.79,"usd_value":2279433,"security_title":"Common Stock","importance":37.27943301},{"ts":"2026-07-06","kind":"sec.filing","form_type":"144","title":"144 — Dyne Therapeutics, Inc. — 2026-07-06","url_slug":"/sec/cik-0001818794/144/0001628280-26-047355","accession_number":"0001628280-26-047355","importance":30},{"ts":"2026-06-29","kind":"sec.form144","reporter":"Atlas Venture Fund XI, LP","title":"Shareholder","shares":102969,"usd_value":2156171,"security_title":"Common","approx_sale_date":"2026-06-29","accession_number":"0001628280-26-046094","importance":40.431234172},{"ts":"2026-06-29","kind":"sec.form144","reporter":"Atlas Venture Opportunity Fund II, LP","title":"Shareholder","shares":51756,"usd_value":1083771,"security_title":"Common","approx_sale_date":"2026-06-29","accession_number":"0001628280-26-046096","importance":40.216754128},{"ts":"2026-06-29","kind":"sec.form144","reporter":"Atlas Venture Opportunity Fund I, LP","title":"Shareholder","shares":40702,"usd_value":852300,"security_title":"Common","approx_sale_date":"2026-06-29","accession_number":"0001628280-26-046093","importance":40.170459976},{"ts":"2026-06-29","kind":"sec.insider.s","reporter":"Rhodes Jason P","title":"","shares":102969,"price_per_share":21.14,"usd_value":2176765,"security_title":"Common Stock","importance":37.17676466},{"ts":"2026-06-29","kind":"sec.insider.s","reporter":"Rhodes Jason P","title":"","shares":51756,"price_per_share":21.14,"usd_value":1094122,"security_title":"Common Stock","importance":36.09412184},{"ts":"2026-06-29","kind":"sec.insider.s","reporter":"Rhodes Jason P","title":"","shares":40702,"price_per_share":21.14,"usd_value":860440,"security_title":"Common Stock","importance":35.86044028},{"ts":"2026-06-29","kind":"sec.filing","form_type":"144","title":"144 — Atlas Venture Opportunity Fund I, L.P. — 2026-06-29","url_slug":"/sec/cik-0001759241/144/0001628280-26-046093","accession_number":"0001628280-26-046093","importance":30},{"ts":"2026-06-29","kind":"sec.filing","form_type":"144","title":"144 — Dyne Therapeutics, Inc. — 2026-06-29","url_slug":"/sec/cik-0001818794/144/0001628280-26-046096","accession_number":"0001628280-26-046096","importance":30},{"ts":"2026-06-26","kind":"sec.form144","reporter":"Atlas Venture Fund XI, LP","title":"Shareholder","shares":162954,"usd_value":3358482,"security_title":"Common","approx_sale_date":"2026-06-26","accession_number":"0001628280-26-045819","importance":40.671696388},{"ts":"2026-06-26","kind":"sec.form144","reporter":"Atlas Venture Opportunity Fund II, LP","title":"Shareholder","shares":81903,"usd_value":1688021,"security_title":"Common","approx_sale_date":"2026-06-26","accession_number":"0001628280-26-045820","importance":40.337604166},{"ts":"2026-06-26","kind":"sec.form144","reporter":"Atlas Venture Opportunity Fund I, LP","title":"Shareholder","shares":64411,"usd_value":1327511,"security_title":"Common","approx_sale_date":"2026-06-26","accession_number":"0001628280-26-045818","importance":40.265502142},{"ts":"2026-06-26","kind":"sec.insider.s","reporter":"Rhodes Jason P","title":"","shares":162954,"price_per_share":21.28,"usd_value":3467661,"security_title":"Common Stock","importance":38.46766112},{"ts":"2026-06-26","kind":"sec.insider.s","reporter":"Rhodes Jason P","title":"","shares":81903,"price_per_share":21.28,"usd_value":1742896,"security_title":"Common Stock","importance":36.74289584},{"ts":"2026-06-26","kind":"sec.insider.s","reporter":"Rhodes Jason P","title":"","shares":64411,"price_per_share":21.28,"usd_value":1370666,"security_title":"Common Stock","importance":36.37066608},{"ts":"2026-06-26","kind":"sec.filing","form_type":"144","title":"144 — Dyne Therapeutics, Inc. — 2026-06-26","url_slug":"/sec/cik-0001818794/144/0001628280-26-045820","accession_number":"0001628280-26-045820","importance":30},{"ts":"2026-06-25","kind":"sec.form144","reporter":"Atlas Venture Fund XI, LP","title":"Shareholder","shares":12699,"usd_value":258171,"security_title":"Common","approx_sale_date":"2026-06-25","accession_number":"0001628280-26-045611","importance":40.051634134},{"ts":"2026-06-25","kind":"sec.form144","reporter":"Atlas Venture Opportunity Fund II, LP","title":"Shareholder","shares":6382,"usd_value":129746,"security_title":"Common","approx_sale_date":"2026-06-25","accession_number":"0001628280-26-045613","importance":40.025949212},{"ts":"2026-06-25","kind":"sec.form144","reporter":"Atlas Venture Opportunity Fund I, LP","title":"Shareholder","shares":5019,"usd_value":102036,"security_title":"Common","approx_sale_date":"2026-06-25","accession_number":"0001628280-26-045612","importance":40.020407254},{"ts":"2026-06-25","kind":"sec.form144","reporter":"Lucera Erick","title":"Officer","shares":2362,"usd_value":48103,"security_title":"Common Stock","approx_sale_date":"2026-06-25","accession_number":"0001972481-26-000209","importance":40.0096206},{"ts":"2026-06-25","kind":"sec.insider.s","reporter":"Rhodes Jason P","title":"","shares":12699,"price_per_share":21.1,"usd_value":267949,"security_title":"Common Stock","importance":35.2679489},{"ts":"2026-06-25","kind":"sec.insider.s","reporter":"Rhodes Jason P","title":"","shares":6382,"price_per_share":21.1,"usd_value":134660,"security_title":"Common Stock","importance":35.1346602},{"ts":"2026-06-25","kind":"sec.insider.s","reporter":"Rhodes Jason P","title":"","shares":5019,"price_per_share":21.1,"usd_value":105901,"security_title":"Common Stock","importance":35.1059009},{"ts":"2026-06-25","kind":"sec.insider.s","reporter":"Lucera Erick","title":"Chief Financial Officer","shares":2362,"price_per_share":20.37,"usd_value":48114,"security_title":"Common Stock","importance":35.04811394},{"ts":"2026-06-25","kind":"sec.filing","form_type":"144","title":"144 — Dyne Therapeutics, Inc. — 2026-06-25","url_slug":"/sec/cik-0001818794/144/0001628280-26-045613","accession_number":"0001628280-26-045613","importance":30},{"ts":"2026-06-24","kind":"sec.form144","reporter":"Atlas Venture Fund XI, LP","title":"Shareholder","shares":50530,"usd_value":1023738,"security_title":"Common","approx_sale_date":"2026-06-24","accession_number":"0001628280-26-045293","importance":40.20474756},{"ts":"2026-06-24","kind":"sec.form144","reporter":"Atlas Venture Opportunity Fund II, LP","title":"Shareholder","shares":25397,"usd_value":514543,"security_title":"Common","approx_sale_date":"2026-06-24","accession_number":"0001628280-26-045297","importance":40.102908644},{"ts":"2026-06-24","kind":"sec.form144","reporter":"Atlas Venture Opportunity Fund I, LP","title":"Shareholder","shares":19973,"usd_value":404653,"security_title":"Common","approx_sale_date":"2026-06-24","accession_number":"0001628280-26-045294","importance":40.080930596},{"ts":"2026-06-24","kind":"sec.insider.s","reporter":"Rhodes Jason P","title":"","shares":50530,"price_per_share":21.02,"usd_value":1062141,"security_title":"Common Stock","importance":36.0621406},{"ts":"2026-06-24","kind":"sec.insider.s","reporter":"Rhodes Jason P","title":"","shares":25397,"price_per_share":21.02,"usd_value":533845,"security_title":"Common Stock","importance":35.53384494},{"ts":"2026-06-24","kind":"sec.insider.s","reporter":"Rhodes Jason P","title":"","shares":19973,"price_per_share":21.02,"usd_value":419832,"security_title":"Common Stock","importance":35.41983246},{"ts":"2026-06-24","kind":"sec.filing","form_type":"144","title":"144 — Dyne Therapeutics, Inc. — 2026-06-24","url_slug":"/sec/cik-0001818794/144/0001628280-26-045297","accession_number":"0001628280-26-045297","importance":30},{"ts":"2026-06-24","kind":"sec.filing","form_type":"4","title":"4 — Dyne Therapeutics, Inc. — 2026-06-24","url_slug":"/sec/cik-0001818794/4/0001193125-26-281119","accession_number":"0001193125-26-281119","importance":30},{"ts":"2026-06-23","kind":"sec.form144","reporter":"Atlas Venture Opportunity Fund II, LP","title":"Shareholder","shares":39131,"usd_value":816664,"security_title":"Common","approx_sale_date":"2026-06-23","accession_number":"0001628280-26-044987","importance":40.163332794},{"ts":"2026-06-23","kind":"sec.insider.s","reporter":"Rhodes Jason P","title":"","shares":77855,"price_per_share":21.13,"usd_value":1645076,"security_title":"Common Stock","importance":36.64507615},{"ts":"2026-06-23","kind":"sec.insider.s","reporter":"Kersten Dirk","title":null,"shares":71629,"price_per_share":21.0357,"usd_value":1506766,"security_title":"Common Stock","importance":36.5067661553},{"ts":"2026-06-23","kind":"sec.insider.s","reporter":"Rhodes Jason P","title":"","shares":39131,"price_per_share":21.13,"usd_value":826838,"security_title":"Common Stock","importance":35.82683803},{"ts":"2026-06-23","kind":"sec.insider.s","reporter":"Rhodes Jason P","title":"","shares":30774,"price_per_share":21.13,"usd_value":650255,"security_title":"Common Stock","importance":35.65025462},{"ts":"2026-06-23","kind":"sec.insider.s","reporter":"Kersten Dirk","title":null,"shares":1657,"price_per_share":21.4742,"usd_value":35583,"security_title":"Common Stock","importance":35.0355827494},{"ts":"2026-06-23","kind":"sec.filing","form_type":"144","title":"144 — Atlas Venture Opportunity Fund I, L.P. — 2026-06-23","url_slug":"/sec/cik-0001759241/144/0001628280-26-044988","accession_number":"0001628280-26-044988","importance":30},{"ts":"2026-06-23","kind":"sec.filing","form_type":"144","title":"144 — Dyne Therapeutics, Inc. — 2026-06-23","url_slug":"/sec/cik-0001818794/144/0001628280-26-044987","accession_number":"0001628280-26-044987","importance":30},{"ts":"2026-06-22","kind":"sec.insider.s","reporter":"Kersten Dirk","title":null,"shares":190676,"price_per_share":20.5703,"usd_value":3922263,"security_title":"Common Stock","importance":38.9222625228},{"ts":"2026-06-22","kind":"sec.filing","form_type":"8-K","title":"8-K — Dyne Therapeutics, Inc. — 2026-06-22","url_slug":"/sec/cik-0001818794/8-k/0001818794-26-000005","accession_number":"0001818794-26-000005","importance":35},{"ts":"2026-06-18","kind":"sec.insider.s","reporter":"Kersten Dirk","title":null,"shares":46901,"price_per_share":20.0715,"usd_value":941373,"security_title":"Common Stock","importance":35.9413734215},{"ts":"2026-06-17","kind":"sec.form144","reporter":"ForDyne B.V.","title":"Affiliate","shares":348317,"usd_value":6384651,"security_title":"Common","approx_sale_date":"2026-06-17","accession_number":"0001969223-26-000712","importance":41.276930122},{"ts":"2026-06-17","kind":"sec.insider.s","reporter":"Kersten Dirk","title":null,"shares":37454,"price_per_share":20.1398,"usd_value":754316,"security_title":"Common Stock","importance":35.7543160692},{"ts":"2026-06-17","kind":"sec.filing","form_type":"8-K","title":"8-K — Dyne Therapeutics, Inc. — 2026-06-17","url_slug":"/sec/cik-0001818794/8-k/0001818794-26-000003","accession_number":"0001818794-26-000003","importance":35},{"ts":"2026-06-17","kind":"sec.filing","form_type":"144","title":"144 — Dyne Therapeutics, Inc. — 2026-06-17","url_slug":"/sec/cik-0001818794/144/0001969223-26-000712","accession_number":"0001969223-26-000712","importance":30},{"ts":"2026-06-17","kind":"sec.filing","form_type":"4","title":"4 — Cox John — 2026-06-17","url_slug":"/sec/cik-0001498428/4/0001498428-26-000002","accession_number":"0001498428-26-000002","importance":30},{"ts":"2026-06-17","kind":"sec.filing","form_type":"4","title":"4 — Dyne Therapeutics, Inc. — 2026-06-17","url_slug":"/sec/cik-0001818794/4/0001915598-26-000002","accession_number":"0001915598-26-000002","importance":30},{"ts":"2026-06-16","kind":"sec.form144","reporter":"Cox John","title":"Officer","shares":2683,"usd_value":49191,"security_title":"Common Stock","approx_sale_date":"2026-06-16","accession_number":"0001972481-26-000203","importance":40.0098382},{"ts":"2026-06-16","kind":"sec.insider.s","reporter":"Cox John","title":"CEO & President","shares":2683,"price_per_share":18.33,"usd_value":49179,"security_title":"Common Stock","importance":35.04917939},{"ts":"2026-06-16","kind":"sec.insider.s","reporter":"Kerr Douglas","title":"Chief Medical Officer","shares":887,"price_per_share":18.33,"usd_value":16259,"security_title":"Common Stock","importance":35.01625871},{"ts":"2026-06-16","kind":"sec.insider.s","reporter":"Friedl-Naderer Johanna","title":"Chief Commercial Officer","shares":145,"price_per_share":18.33,"usd_value":2658,"security_title":"Common Stock","importance":35.00265785},{"ts":"2026-06-09","kind":"sec.filing","form_type":"4","title":"4 — Posner Brian S — 2026-06-09","url_slug":"/sec/cik-0001372455/4/0001193125-26-264004","accession_number":"0001193125-26-264004","importance":30},{"ts":"2026-06-09","kind":"sec.filing","form_type":"4","title":"4 — Dyne Therapeutics, Inc. — 2026-06-09","url_slug":"/sec/cik-0001818794/4/0001193125-26-264019","accession_number":"0001193125-26-264019","importance":30},{"ts":"2026-06-09","kind":"sec.filing","form_type":"4","title":"4 — Dyne Therapeutics, Inc. — 2026-06-09","url_slug":"/sec/cik-0001818794/4/0001193125-26-264021","accession_number":"0001193125-26-264021","importance":30},{"ts":"2026-06-08","kind":"sec.insider.p","reporter":"Posner Brian S","title":null,"shares":2000,"price_per_share":16.94,"usd_value":33880,"security_title":"Common Stock","importance":50.03388},{"ts":"2026-06-08","kind":"sec.filing","form_type":"8-K","title":"8-K — Dyne Therapeutics, Inc. — 2026-06-08","url_slug":"/sec/cik-0001818794/8-k/0001193125-26-261696","accession_number":"0001193125-26-261696","importance":35},{"ts":"2026-06-03","kind":"sec.insider.p","reporter":"Posner Brian S","title":null,"shares":2500,"price_per_share":17.48,"usd_value":43700,"security_title":"Common Stock","importance":50.0437},{"ts":"2026-06-03","kind":"sec.filing","form_type":"8-K","title":"8-K — Dyne Therapeutics, Inc. — 2026-06-03","url_slug":"/sec/cik-0001818794/8-k/0001193125-26-254597","accession_number":"0001193125-26-254597","importance":35},{"ts":"2026-05-15","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — Dyne Therapeutics, Inc. — 2026-05-15","url_slug":"/sec/cik-0001818794/schedule-13g-a/0001897612-26-000494","accession_number":"0001897612-26-000494","importance":30},{"ts":"2026-05-14","kind":"sec.filing","form_type":"4","title":"4 — Dyne Therapeutics, Inc. — 2026-05-14","url_slug":"/sec/cik-0001818794/4/0001193125-26-223984","accession_number":"0001193125-26-223984","importance":30},{"ts":"2026-05-13","kind":"sec.form144","reporter":"Cox John","title":"Officer","shares":3311,"usd_value":60805,"security_title":"Common Stock","approx_sale_date":"2026-05-13","accession_number":"0001972481-26-000156","importance":40.012161},{"ts":"2026-05-13","kind":"sec.form144","reporter":"Lucera Erick","title":"Officer","shares":1448,"usd_value":26592,"security_title":"Common Stock","approx_sale_date":"2026-05-13","accession_number":"0001972481-26-000155","importance":40.0053184},{"ts":"2026-05-13","kind":"sec.insider.s","reporter":"Cox John","title":"CEO & President","shares":3311,"price_per_share":18.36,"usd_value":60790,"security_title":"Common Stock","importance":35.06078996},{"ts":"2026-05-13","kind":"sec.insider.s","reporter":"Kerr Douglas","title":"Chief Medical Officer","shares":1564,"price_per_share":18.36,"usd_value":28715,"security_title":"Common Stock","importance":35.02871504},{"ts":"2026-05-13","kind":"sec.insider.s","reporter":"Lucera Erick","title":"Chief Financial Officer","shares":1448,"price_per_share":18.36,"usd_value":26585,"security_title":"Common Stock","importance":35.02658528},{"ts":"2026-05-13","kind":"sec.insider.s","reporter":"Friedl-Naderer Johanna","title":"Chief Commercial Officer","shares":228,"price_per_share":18.36,"usd_value":4186,"security_title":"Common Stock","importance":35.00418608},{"ts":"2026-05-06","kind":"clinical.trial","reporter":"Dyne Therapeutics","title":"Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07486934","excerpt":"[\"Myotonic Dystrophy Type 1 (DM1)\",\"DM1\",\"Myotonic Dystrophy\",\"Steinert Disease\",\"Steinert\"]","importance":60},{"ts":"2026-04-27","kind":"sec.form144","reporter":"Atlas Venture Opportunity Fund II, LP","title":"Shareholder","shares":45709,"usd_value":834646,"security_title":"Common","approx_sale_date":"2026-04-27","accession_number":"0001628280-26-027569","importance":40.166929268},{"ts":"2026-04-27","kind":"sec.form144","reporter":"Atlas Venture Associates XI, LP","title":"Shareholder","shares":894,"usd_value":16324,"security_title":"Common","approx_sale_date":"2026-04-27","accession_number":"0001628280-26-027561","importance":40.003264888},{"ts":"2026-04-27","kind":"sec.insider.s","reporter":"Rhodes Jason P","title":"","shares":90943,"price_per_share":18.15,"usd_value":1650615,"security_title":"Common Stock","importance":36.65061545},{"ts":"2026-04-27","kind":"sec.insider.s","reporter":"Rhodes Jason P","title":"","shares":45709,"price_per_share":18.15,"usd_value":829618,"security_title":"Common Stock","importance":35.82961835},{"ts":"2026-04-27","kind":"sec.insider.s","reporter":"Rhodes Jason P","title":"","shares":35947,"price_per_share":18.15,"usd_value":652438,"security_title":"Common Stock","importance":35.65243805},{"ts":"2026-04-27","kind":"sec.insider.s","reporter":"Rhodes Jason P","title":"","shares":894,"price_per_share":18.15,"usd_value":16226,"security_title":"Common Stock","importance":35.0162261},{"ts":"2026-04-24","kind":"sec.insider.s","reporter":"Rhodes Jason P","title":"","shares":72310,"price_per_share":18.48,"usd_value":1336289,"security_title":"Common Stock","importance":36.3362888},{"ts":"2026-04-24","kind":"sec.insider.s","reporter":"Rhodes Jason P","title":"","shares":36345,"price_per_share":18.48,"usd_value":671656,"security_title":"Common Stock","importance":35.6716556}]}